Valuation: Waldencast plc

Market Cap 116M 103M 96.52M 87.67M 165M 11.2B 166M 1.16B 453M 5.7B 435M 425M 18.31B P/E 2026 *
-1.94x
P/E 2027 * -2.2x
Enterprise Value 116M 103M 96.52M 87.67M 165M 11.2B 166M 1.16B 453M 5.7B 435M 425M 18.31B EV / Sales 2026 *
0.4x
EV / Sales 2027 * 0.36x
Free-Float
44.64%
Yield 2026 *
-
Yield 2027 * -
09-24 Waldencast Files to Delist Shares, Warrants From Nasdaq MT
09-20 Waldencast plc(NasdaqCM:WALD) added to S&P Global BMI Index CI
09-14 Top Premarket Decliners MT
09-14 Waldencast Plans Voluntary Nasdaq Delisting; Shares Down Pre-Bell MT
07-29 Bridgepoint Europe VII and Bridgepoint Europe VII 2 LP, funds managed by Bridgepoint Advisers Limited, and Gore Range Capital Fund III Llc, a fund managed by Gore Range Capital LLC, acquired Obagi Cosmeceuticals LLC, Obagi Netherlands B.V. and Obagi AsiaPac Limited from Waldencast plc. CI
06-15 Waldencast plc Announces Fda Approval of Obagi Saypha Chiq Injectable Hyaluronic Acid Gel CI
06-15 Waldencast Says US FDA Approves Obagi Saypha ChIQ Injectable Hyaluronic Acid Gel MT
06-01 Waldencast plc Announces CEO Changes CI
06-01 Waldencast plc Announces Board Changes, Effective June 1, 2026 CI
06-01 Waldencast announces sale of Obagi Medical to Bridgepoint RE
05-31 Bridgepoint Europe VII and Bridgepoint Europe VII 2 LP, funds managed by Bridgepoint Advisers Limited, and Gore Range Capital Fund III Llc, a fund managed by Gore Range Capital LLC, entered into a definitive agreement to acquire Obagi Cosmeceuticals LLC, Obagi Netherlands B.V. and Obagi AsiaPac Limited from Waldencast plc for $460 million. CI
05-15 Obagi Medical Shares New Data on Recent Innovations At Music City Symposium for Cosmetic Advances and Laser Education Meeting CI
05-14 Obagi Medical And Next Health Form Strategic Alliance To Launch The Skin Recharge Station Pop-Up Experience CI
1 day-7.62%
Current month-86.89%
Current year-86.89%
5 years 0.97
Extreme 0.97
10.89
10 years 0.97
Extreme 0.97
11.32
Manager TitleAgeSince
Chief Executive Officer 60 2026-07-29
General Counsel - 2023-08-31
Director TitleAgeSince
Chairman 60 2020-12-31
Director/Board Member 60 2021-11-30
Director/Board Member 52 2021-02-28
Change 5-day change 1-year change 3-year change Capi.($)
-7.62%+12.86% - - 125M
-0.33%-0.13%-2.03%+40.00% 23.4B
+0.71%+3.93%-39.45%-20.48% 16.82B
-2.27%-0.59%-20.58% - 16.15B
-2.74%-2.32%-41.68%+26.76% 11.99B
-0.60%+0.39%+28.43% - 11.59B
-1.94%+0.29%-22.67%+156.09% 9.22B
+0.44%+0.11%-51.58%-2.83% 7.29B
-0.46%-2.36%+0.33%+33.48% 7.1B
+0.06%+2.82%+18.95%+15.84% 5.23B
Average -1.44%+0.33%-14.48%+35.55% 12.09B
Weighted average by Cap. -0.81%+0.26%-15.60%+32.71%

Financials

2026 *2027 *
Net sales 287M 256M 239M 217M 409M 27.72B 412M 2.87B 1.12B 14.1B 1.08B 1.05B 45.32B 318M 284M 265M 240M 453M 30.72B 456M 3.18B 1.24B 15.62B 1.19B 1.17B 50.23B
Net income -57.81M -51.65M -48.19M -43.77M -82.43M -5.59B -83.05M -579M -226M -2.84B -217M -212M -9.14B -51.81M -46.3M -43.19M -39.23M -73.89M -5.01B -74.44M -519M -203M -2.55B -195M -190M -8.19B
Net Debt - -
Projected Income Statement - Annual - Waldencast plc
Logo Waldencast plc
Waldencast plc is a global multi-brand beauty and wellness platform. It is focused on developing, acquiring, accelerating, and scaling conscious and purpose-driven brands. Its segments include Obagi Medical and Milk Makeup. The Obagi Medical segment sells advanced skincare products backed by science and formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines and wrinkles, and to protect and enhance skin tone and texture. Its portfolio of medical-grade skincare with consumer-centric, in-office injectable procedures includes Saypha ChIQ, and MagIQ lines of injectable hyaluronic acid gels. The Milk Makeup segment consists of the business of Milk. Its Milk’s business activities include developing, marketing, and selling cosmetics, skincare, and other beauty products. Its Milk Makeup segment offers over 250 products through its United States Website www.MilkMakeup.com and retail partners include Sephora globally and Ulta Beauty in the United States.
Employees
367
Date Price Change
26-10-07 US$0.9700 -7.62%
26-10-06 US$1.050 +10.53%
26-10-05 US$0.9500 +8.03%
26-10-02 US$0.8794 -4.69%
26-10-01 US$0.9227 +7.35%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Waldencast plc
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.050USD
Average target price
2.050USD
Spread / Average Target
+95.24%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Waldencast plc